NED Biosystems strengthened its Board of Directors with the appointment of a highly accomplished physician-scientist and biotechnology executive, José Trevejo, MD, PhD. The appointment of Dr. Trevejo, who has led organizations in the development of high impact medicines spanning multiple therapeutic areas, will bring a key life sciences expertise to the Board. His current work in developing transformative therapies using nature’s chemistry is also well aligned with NED’s own incorporation of natural substances into systems-based approaches that promise to transform how cancer patients are treated globally.
Dr. Trevejo is currently the Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Biosciences which is developing new medicines from natural products utilizing AI. Prior to Enveda he was the CMO of Tarsus Pharma where he helped lead the FDA approval and successful launch of a novel category-creating ophthalmology drug. Dr. Trevejo also served as CDO for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, Dr. Trevejo held increasing roles of responsibility at Ironwood, Genentech and Vertex Pharmaceuticals. Dr. Trevejo received his M.D. and Ph.D. at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional M.D./Ph.D. Program and completed his residency and specialty training at Harvard Medical School affiliates BWH and BIDMC.
Dr. Trevejo will support NED’s mission as a Delaware Public Benefit Corporation to reach patients across the globe who currently lack access to care.
About NED Biosystems:
Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company focused on patients and their families. NED’s mission is to enable patients to achieve and sustain No Evidence of Disease. The Company’s novel platform has designed treatments to address large unmet needs for cancer and infectious disease patients. The intent is to achieve what today’s HIV treatments have: to transform what may be a death sentence diagnosis to No Disease, or reliably managed disease with quality of life.
NED’s novel platform pioneers a data-driven methodology. By simultaneously and redundantly affecting the processes driving disease, well-established by decades of research, treatments are designed to arrest disease progression and normalize disease-related imbalances. Deploying safe, evidenced-based agents lacking customary toxicity and side effects, NED’s treatments are comprehensive unlike today’s narrowly targeted therapies.
NED is a Delaware Public Benefit Company seeking to make its therapies accessible in both developed and developing countries.
For more information, visit https://nedbiosystems.com/.
For additional information regarding this press release, please contact info@nedbiosystems.com.
PHOTO links for media:
https://nedbiosystems.com/wp-content/uploads/2020/07/Trevejo-Jose_square-low-res-e1733927422620.jpg
Caption: José Trevejo, MD, PhD, NED Biosystems’ New Director to the Board.
